More 340B Legislation Released, Sharpening Where -- and How -- Reform Might Happen

And Lilly bakes the CMS Bridge demo into its ad campaigns

Fox Business Shows How Mainstream Interest in 340B Is Building

CMS Again Targets 340B Hospitals With a Plan for Massive Reimbursement Cuts on Discounted Drugs

Plus assessing whether CMS’ Bridge program will be ginormous or merely huge

The Three Stories You’ll See Over and Over as the CMS Obesity ‘Bridge’ Program Launches on Wednesday

Bill Cassidy Is Leaving Congress a Blueprint for 340B Reform

And trying to make sense of an ADA poll showing that most patients with diabetes pay more than $35 a month for insulin

A CMS Bridge Demo Irony: Patients With Obesity and Diabetes May Pay 3x What Patients With Only Obesity Pay

And drug launch prices fell like a rock last year (but you can’t really read anything into that)

Trump Weighs In on CMS’ Bridge as the Countdown to Launch Reaches T-Minus One Week

And pharma companies take aim at the reluctance of European countries to boost medicine spending

CMS’ Obesity ‘Bridge’ Demo Will Launch Next Week, and Everyone Is Scrambling to Explain How It Will Work

And a 340B hospital in Virginia finds a novel way of not helping vulnerable patients

A Post-Long-Weekend Top 10, Led by U.S.-Germany Trade Drama and Bridge Specifics

Plus a couple of 340B links and a study on the impact of the Medicare Part D out-of-pocket cap

Europe to Struggle With a Unified MFN Approach to Ensure No Country Gets ‘Played’ by the U.S.

And a new report adds up the impact on drug development from the chaos across the innovation ecosystem

Democrats Lay Out a Litany of Price-Lowering Ideas for Drugs (But Fail to Ask the Most Important Question)

And the Trump administration moves ahead with MFN rules as European governments weigh the impacts

CMS Proposes Codifying Rules for How It Will Run Drug Negotiations

CMS’s efforts include a change to how and when certain blockbusters get Medicare-set prices

White House Claims a ‘Significant’ Number of Companies Have Elected to Join MFN-in-Medicaid Model

And HHS is taking the next step in transitioning toward a 340B ‘rebate model’

A Key Deadline for Companies Seeking MFN Deals Has Arrived

And Pfizer’s CEO sends a letter to Germany’s leader: ”We are ​reviewing ... certain planned investments in Germany”

Politico Says the U.S. and Germany Are In ‘Secret Talks’ About MFN

And PCMA releases a document that is a master class in finger-pointing

CMS Will Need to Bridge Beyond the ‘Bridge’ Demo to Preserve Long-Term Access to Obesity Meds in Medicare

And I have the numbers on TrumpRx’s web visit numbers for May

It’s All Obesity Today: Drama at ADA, Pricing Implications for Pfizer’s Med, and WSJ on Shrinking Employer Coverage

Plus: ‘Why would you threaten 50% of your revenue if you think you cannot get a reasonable price in the UK or France?’

Supreme Court Addresses ‘Skinny Labeling’ for Generic Drugs

And Pfizer’s Impact Report is out, detailing how the company’s portfolio-wide net price shifted in 2025

An Apex Grab Bag on Value-Based Insurance, Investments in Europe, and Ongoing 340B Battles

TrumpRx Traffic Numbers, Touted by Oz, Appear to Be Falling

And the top of the Fortune 500 list is a who’s-who companies profiting from 340B

Lilly Says Smaller Clinics Have No Problems With 340B Transparency Acts, Even as Big, Profitmaxxing Hospitals Object

The Irony of PCMA Celebrating a PBM Selection Process Won By a Big-PBM Critic

And assessing the unknowns around the plan to reimburse obesity meds in Medicare, which kicks off in a month

Oncology, Long Shielded From Payer Access Challenges, Has Begun to See More Restrictions

And Takeda says that its net prices fell last year

How Will MFN Impact the Pricing of Three Newly Approved Meds?

And advocates for rural 340B providers seek to ensure that urban hospitals don’t abuse 340B provisions intended for rural facilities

Bausch Pulled Out of Medicaid. Then the Price Hikes Began.

And the single most important health-wonk image of the year (so far)